1. Patients with newly diagnosed previously untreated resectable NSCLC (tumors ≥ 4 cm and/or node positive) and no known EGFR mutations or ALK rearrangements prescribed with durvalumab as per local prescriber information.
2. Provision of signed, written and dated informed consent
You may not be if
1. Presence of unresectable or metastatic disease.
2. Prior treatment with durvalumab for any other indications
3. Requires concurrent treatment for cancers other than resectable NSCLC
4. Concurrently participating in any other clinical trial
5. Patients with active or prior autoimmune disease or with medical conditions that required systemic corticosteroids or immunosuppressants
6. Any condition that, in the opinion of the investigator, would interfere with the patient's participation in the study.
